In the recent years, the advent of immunotherapy based on immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein-1 (PD1)/ligand-1 (PD-L1) pathway has revolutionized systemic treatment of renal cell carcinoma (RCC). Here, PDCD1 is linked to hereditary clear cell renal cell carcinoma.